{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:02:33Z","timestamp":1783702953001,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T00:00:00Z","timestamp":1669420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T00:00:00Z","timestamp":1669420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and objectives<\/jats:title>\n                <jats:p>Inflammatory bowel disease (IBD) is a chronic systemic inflammatory condition that debilitate the quality of life. Multimorbidity, a concept only beginning to emerge in IBD, is defined as two or more comorbidities present in the same individual. Notably, we used the term multimorbidity to refer to two or more comorbidities excluding IBD. Multimorbidity is linked to decreased quality of life, poorer disease outcomes, increased hospitalizations, healthcare costs and polypharmacy complications. We aim to estimate the prevalence of multimorbidity and to explore its effect on IBD patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively reviewed all IBD patients registered in a validated web-based registry since February 2018. Data on patient demographics, comorbidities, IBD and extraintestinal complications were obtained. We analyzed the date using univariate, bivariate and multivariable analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 767 IBD patients, 54.6% had Crohn\u2019s disease (CD), 41.9% had ulcerative colitis (UC) and 3.5% had IBD unclassified. The median age at diagnosis was 22 years (IQR: 15\u201329). Males compromised 50.2% of patients. According to the Montr\u00e9al IBD classification, most UC patients had moderate UC (47.8%) while most CD patients had non-stricturing non-penetrating CD (49.8%). Overall, 10.3% IBD patients had multimorbidity and 23.9% had at least one comorbidity. The most common comorbidity was diabetes mellitus (4.9%) followed by essential hypertension (4%) and iron deficiency anemia (3%). Female gender (P\u2009=\u20090.008) and UC (<jats:italic>P<\/jats:italic>\u2009=\u20090.005) were more likely to have multimorbidity. Multimorbid IBD patients were more likely to develop thrombosis than non-multimorbid peers (16.7% vs. 1.6%; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Higher age at diagnosis (OR\u2009=\u20091.04, 95%CI: 1.01\u20131.07) and having a history of thrombosis (OR\u2009=\u20097.82, 95% CI: 2.67\u201322.92) are associated with increased risk of multimorbidity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Multimorbidity is not uncommon among IBD patients, especially females diagnosed with UC. Our findings indicate that future studies are needed to explore the effects of multimorbidity on IBD patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-022-02578-2","type":"journal-article","created":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T01:19:13Z","timestamp":1669511953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Multimorbidity among inflammatory bowel disease patients in a tertiary care center: a retrospective study"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6975-1297","authenticated-orcid":false,"given":"Mahmoud H.","family":"Mosli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Alsahafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad N","family":"Alsanea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Alhasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Saadah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,26]]},"reference":[{"issue":"2","key":"2578_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3109\/13814789609162146","volume":"2","author":"M van den Akker","year":"1996","unstructured":"van den Akker M, Buntinx F, Knottnerus JA. Comorbidity or multimorbidity: what\u2019s in a name? A review of literature. Eur J Gen Pract. 1996;2(2):65\u201370.","journal-title":"Eur J Gen Pract."},{"issue":"8","key":"2578_CR2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S2468-1253(19)30173-6","volume":"4","author":"M Argollo","year":"2019","unstructured":"Argollo M, Gilardi D, Peyrin-Biroulet C, Chabot JF, Peyrin-Biroulet L, Danese S. Comorbidities in inflammatory bowel disease: a call for action. Lancet Gastroenterol Hepatol. 2019;4(8):643\u201354.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"1","key":"2578_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","volume":"1","author":"NA Molodecky","year":"2012","unstructured":"Molodecky NA, Soon S, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012 Jan;1(1):46\u201354. 142(.","journal-title":"Gastroenterology"},{"issue":"6","key":"2578_CR4","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","volume":"140","author":"J Cosnes","year":"2011","unstructured":"Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785\u201394.","journal-title":"Gastroenterology."},{"key":"2578_CR5","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1056\/NEJMra0804647","volume":"361","author":"C Abraham","year":"2009","unstructured":"Abraham C. i Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066\u201378.","journal-title":"N Engl J Med"},{"issue":"5","key":"2578_CR6","first-page":"1064","volume":"98","author":"T Longobardi","year":"2003","unstructured":"Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol. 2003;98(5):1064\u201372.","journal-title":"Am J Gastroenterol."},{"issue":"7","key":"2578_CR7","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1136\/gutjnl-2017-314015","volume":"67","author":"J Kirchgesner","year":"2018","unstructured":"Kirchgesner J, Beaugerie L, Carrat F, Andersen NN, Jess T, Schwarzinger M. Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study. Gut. 2018;67(7):1261\u20138.","journal-title":"Gut."},{"key":"2578_CR8","first-page":"38","volume":"11","author":"J Hartmann","year":"2011","unstructured":"Hartmann J, Hehner S, Hemmrich K, K\u00f6rs B, M\u00f6hlmann T. Providing better care at lower cost for multimorbid patients. Health Int. 2011;11:38\u201347.","journal-title":"Health Int"},{"issue":"1","key":"2578_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2318-14-75","volume":"14","author":"JM Abad-D\u00edez","year":"2014","unstructured":"Abad-D\u00edez JM, Calder\u00f3n-Larra\u00f1aga A, Poncel-Falc\u00f3 A, Poblador-Plou B, Calder\u00f3n-Meza JM, Sicras-Mainar A, Clerencia-Sierra M, Prados-Torres A. Age and gender differences in the prevalence and patterns of multimorbidity in the older population. BMC Geriatr. 2014 Dec;14(1):1\u20138.","journal-title":"BMC Geriatr"},{"issue":"12","key":"2578_CR10","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/jech.2009.088260","volume":"64","author":"GE Caughey","year":"2010","unstructured":"Caughey GE, Ramsay EN, Vitry AI, Gilbert AL, Luszcz MA, Ryan P, Roughead EE. Comorbid chronic diseases, discordant impact on mortality in older people: a 14-year longitudinal population study. J Epidemiol Commun Health. 2010;64(12):1036\u201342.","journal-title":"J Epidemiol Commun Health."},{"issue":"1","key":"2578_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/epirev\/mxs009","volume":"35","author":"ME Salive","year":"2013","unstructured":"Salive ME. Multimorbidity in older adults. Epidemiol Rev. 2013;35(1):75\u201383.","journal-title":"Epidemiol Rev."},{"issue":"8","key":"2578_CR12","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1097\/MEG.0000000000000891","volume":"29","author":"C B\u00e4hler","year":"2017","unstructured":"B\u00e4hler C, Schoepfer AM, Vavricka SR, Br\u00fcngger B, Reich O. Chronic comorbidities associated with inflammatory bowel disease: prevalence and impact on healthcare costs in Switzerland. Eur J Gastroenterol Hepatol. 2017;29(8):916\u201325.","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"1","key":"2578_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.crohns.2010.09.008","volume":"5","author":"J Haapam\u00e4ki","year":"2011","unstructured":"Haapam\u00e4ki J, Roine RP, Turunen U, F\u00e4rkkil\u00e4 MA, Arkkila PE. Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. J Crohns Colitis. 2011;5(1):41\u20137. doi:https:\/\/doi.org\/10.1016\/j.crohns.2010.09.008.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"2578_CR14","doi-asserted-by":"publisher","first-page":"e0152559","DOI":"10.1371\/journal.pone.0152559","volume":"11","author":"SM Bahijri","year":"2016","unstructured":"Bahijri SM, Jambi HA, Al Raddadi RM, Ferns G, Tuomilehto J. The prevalence of diabetes and prediabetes in the adult population of Jeddah, Saudi Arabia-a community-based survey. PLoS One. 2016;11(4):e0152559.","journal-title":"PLoS One"},{"issue":"1","key":"2578_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4103\/0256-4947.75773","volume":"31","author":"KA Alqurashi","year":"2011","unstructured":"Alqurashi KA, Aljabri KS, Bokhari SA. Prevalence of diabetes mellitus in a saudi community. Ann Saudi Med. 2011 Jan;31(1):19\u201323.","journal-title":"Ann Saudi Med"},{"issue":"6","key":"2578_CR16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.crohns.2013.09.021","volume":"8","author":"M Fumery","year":"2014","unstructured":"Fumery M, Xiaocang C, Dauchet L, Gower-Rousseau C, Peyrin-Biroulet L, Colombel JF. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohns Colitis. 2014;8(6):469\u201379. doi:https:\/\/doi.org\/10.1016\/j.crohns.2013.09.021.","journal-title":"J Crohns Colitis"},{"issue":"10","key":"2578_CR17","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/apt.12294","volume":"37","author":"H Yuhara","year":"2013","unstructured":"Yuhara H, Steinmaus C, Corley D, et al. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37(10):953\u201362. doi:https:\/\/doi.org\/10.1111\/apt.12294.","journal-title":"Aliment Pharmacol Ther"},{"key":"2578_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.thromres.2019.02.017","volume":"177","author":"N Lange","year":"2019","unstructured":"Lange N, M\u00e9an M, Stalder O, et al. Anticoagulation quality and clinical outcomes in multimorbid elderly patients with acute venous thromboembolism. Thromb Res. 2019;177:10\u20136. doi:https:\/\/doi.org\/10.1016\/j.thromres.2019.02.017.","journal-title":"Thromb Res"},{"key":"2578_CR19","unstructured":"Kochar B, Pate V, Kappelman MD, Long MD, Ananthakrishnan AN, Chan AT, Sandler RS. Vedolizumab is Associated with a lower risk of Serious Infections Than Anti-TNF Agents in older adults. Clinical Gastroenterology and Hepatology. 2021 Sep 3."},{"key":"2578_CR20","first-page":"1","volume":"27","author":"PA Olivera","year":"2021","unstructured":"Olivera PA, Zuily S, Kotze PG, Regnault V, Al Awadhi S, Bossuyt P, Gearry RB, Ghosh S, Kobayashi T, Lacolley P, Louis E. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. NatRev Gastroenterol Hepatol. 2021;27:1\u20137.","journal-title":"NatRev Gastroenterol Hepatol."}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02578-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-022-02578-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02578-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T01:20:35Z","timestamp":1669512035000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-022-02578-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,26]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2578"],"URL":"https:\/\/doi.org\/10.1186\/s12876-022-02578-2","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,26]]},"assertion":[{"value":"6 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Verbal informed consent was obtained from all participants as approved by the institutional review board of King Abdulaziz University Hospital (KAUH). The ethical approval was obtained from the institutional review board of King Abdulaziz University Hospital (Reference number: 433\u2009\u2212\u200921).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest related to this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing of interests"}}],"article-number":"487"}}